Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications

NCT04024436 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT04024436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04024436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 28, 2020
Completion date
September 6, 2023
Enrollment
64 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr 1 high amplification, fgfr2 amplification, metastatic breast cancer